In Situ Silver-Based Electrochemical Oncolytic Bioreactor

In Situ Silver-Based Electrochemical Oncolytic Bioreactor

© 2022 The Authors. Advanced Materials published by Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 34(2022), 40 vom: 01. Okt., Seite e2109973
1. Verfasser: Huang, Yong (VerfasserIn)
Weitere Verfasser: Zhong, Liping, Li, Xiaotong, Wu, Pan, He, Jian, Tang, Chao, Tang, Zhiping, Su, Jing, Feng, Zhenbo, Wang, Bing, Ma, Yun, Peng, Hongmei, Bai, Zhihao, Zhong, Yi, Liang, Ying, Lu, Wenxi, Luo, Ruiyu, Li, Jinghua, Li, Haiping, Deng, Zhiming, Lan, Xianli, Liu, Ziqun, Zhang, Kun, Zhao, Yongxiang
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article 5,5′,6,6′-tetrachloro-1,1,3,3′-tetraethylbenzimidazolyl carbocyanine iodide aptamer targeting intratumoral silver-based nanosynthetic prodrugs primate biosafety silver-based electrochemical oncolytic bioreactors Prodrugs Reducing Agents graphene oxide Silver mehr... 3M4G523W1G Graphite 7782-42-5 Ascorbic Acid PQ6CK8PD0R
LEADER 01000caa a22002652 4500
001 NLM345169980
003 DE-627
005 20240506232041.0
007 cr uuu---uuuuu
008 231226s2022 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202109973  |2 doi 
028 5 2 |a pubmed24n1399.xml 
035 |a (DE-627)NLM345169980 
035 |a (NLM)35998517 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Huang, Yong  |e verfasserin  |4 aut 
245 1 0 |a In Situ Silver-Based Electrochemical Oncolytic Bioreactor 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 07.10.2022 
500 |a Date Revised 06.05.2024 
500 |a published: Print-Electronic 
500 |a ErratumIn: Adv Mater. 2024 May 6;:e2405169. - PMID 38708809 
500 |a Citation Status MEDLINE 
520 |a © 2022 The Authors. Advanced Materials published by Wiley-VCH GmbH. 
520 |a In this study, it is shown for the first time that a reduced graphene oxide (rGO) carrier has a 20-fold higher catalysis rate than graphene oxide in Ag+ reduction. Based on this, a tumor microenvironment-enabled in situ silver-based electrochemical oncolytic bioreactor (SEOB) which switched Ag+ prodrugs into in situ therapeutic silver nanoparticles with and above 95% transition rate is constructed to inhibit the growths of various tumors. In this SEOB-enabled intratumoral nanosynthetic medicine, intratumoral H2 O2 and rGO act as the reductant and the catalyst, respectively. Chelation of aptamers to the SEOB-unlocked prodrugs increases the production of silver nanoparticles in tumor cells, especially in the presence of Vitamin C, which is broken down in tumor cells to supply massive amounts of H2 O2 . Consequently, apoptosis and pyroptosis are induced to cooperatively contribute to the considerably-elevated anti-tumor effects on subcutaneous HepG2 and A549 tumors and orthotopic implanted HepG2 tumors in livers of nude mice. The specific aptamer targeting and intratumoral silver nanoparticle production guarantee excellent biosafety since it fails to elicit tissue damages in monkeys, which greatly increases the clinical translation potential of the SEOB system 
650 4 |a Journal Article 
650 4 |a 5,5′,6,6′-tetrachloro-1,1,3,3′-tetraethylbenzimidazolyl carbocyanine iodide 
650 4 |a aptamer targeting 
650 4 |a intratumoral silver-based nanosynthetic prodrugs 
650 4 |a primate biosafety 
650 4 |a silver-based electrochemical oncolytic bioreactors 
650 7 |a Prodrugs  |2 NLM 
650 7 |a Reducing Agents  |2 NLM 
650 7 |a graphene oxide  |2 NLM 
650 7 |a Silver  |2 NLM 
650 7 |a 3M4G523W1G  |2 NLM 
650 7 |a Graphite  |2 NLM 
650 7 |a 7782-42-5  |2 NLM 
650 7 |a Ascorbic Acid  |2 NLM 
650 7 |a PQ6CK8PD0R  |2 NLM 
700 1 |a Zhong, Liping  |e verfasserin  |4 aut 
700 1 |a Li, Xiaotong  |e verfasserin  |4 aut 
700 1 |a Wu, Pan  |e verfasserin  |4 aut 
700 1 |a He, Jian  |e verfasserin  |4 aut 
700 1 |a Tang, Chao  |e verfasserin  |4 aut 
700 1 |a Tang, Zhiping  |e verfasserin  |4 aut 
700 1 |a Su, Jing  |e verfasserin  |4 aut 
700 1 |a Feng, Zhenbo  |e verfasserin  |4 aut 
700 1 |a Wang, Bing  |e verfasserin  |4 aut 
700 1 |a Ma, Yun  |e verfasserin  |4 aut 
700 1 |a Peng, Hongmei  |e verfasserin  |4 aut 
700 1 |a Bai, Zhihao  |e verfasserin  |4 aut 
700 1 |a Zhong, Yi  |e verfasserin  |4 aut 
700 1 |a Liang, Ying  |e verfasserin  |4 aut 
700 1 |a Lu, Wenxi  |e verfasserin  |4 aut 
700 1 |a Luo, Ruiyu  |e verfasserin  |4 aut 
700 1 |a Li, Jinghua  |e verfasserin  |4 aut 
700 1 |a Li, Haiping  |e verfasserin  |4 aut 
700 1 |a Deng, Zhiming  |e verfasserin  |4 aut 
700 1 |a Lan, Xianli  |e verfasserin  |4 aut 
700 1 |a Liu, Ziqun  |e verfasserin  |4 aut 
700 1 |a Zhang, Kun  |e verfasserin  |4 aut 
700 1 |a Zhao, Yongxiang  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 34(2022), 40 vom: 01. Okt., Seite e2109973  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnns 
773 1 8 |g volume:34  |g year:2022  |g number:40  |g day:01  |g month:10  |g pages:e2109973 
856 4 0 |u http://dx.doi.org/10.1002/adma.202109973  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 34  |j 2022  |e 40  |b 01  |c 10  |h e2109973